Literature DB >> 9476905

Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors.

V Gouyer1, S Gazzéri, I Bolon, C Drevet, C Brambilla, E Brambilla.   

Abstract

The retinoblastoma (RB) gene plays a key role in cell cycle control by regulation of G1 growth arrest. This gene is inactivated in some human cancers and in most small-cell lung carcinoma (SCLC) cell lines. The aim of this study was to analyze the mechanisms of RB silencing in freshly excised neuroendocrine (NE) tumors embracing the entire spectrum of NE lung neoplasms (typical and atypical carcinoids, large-cell neuroendocrine carcinomas [LCNECs], and SCLCs). To study the role and mechanism of RB inactivation in tumor differentiation and malignant potential, the status of the Rb protein was analyzed in 37 NE lung tumors, using immunohistochemistry with five Rb antibodies. Loss or altered expression of Rb protein was more frequently observed in high-grade NE lung carcinoma (23 of 28, 82%) than in typical and atypical carcinoids (1 of 9, 11%) (P < 0.001). Of 24 tumors with abnormal Rb staining, Southern blotting showed 1 to have undergone rearrangement, SSCP (single-strand conformation polymorphism) and sequencing showed that 6 (25%) exhibited mutations in exons 13-18 or 20-24 of the RB gene, and RT-PCR (reverse transcriptase-polymerase chain reaction) revealed that 14 (58%) showed a low level of or entirely absent RB mRNA (messenger RNA) expression, whereas hypermethylation of the CpG-rich island at the 5' end of the RB gene was not observed. Abnormal Rb protein expression was always associated with one of these three alternative mechanisms in the SCLCs analyzed, but in only 50% of LCNECs. These results indicate that inactivation of the RB gene is highly frequent in freshly excised high-grade NE lung tumors through distinct mechanisms including point mutations and frequent abnormal mRNA expression. Different modes of RB inactivation seem to be implicated along the spectrum of NE lung carcinomas, depending on differentiation state, phenotype, and malignancy grade.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9476905     DOI: 10.1165/ajrcmb.18.2.3008

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  16 in total

Review 1.  Smoking, p53 mutation, and lung cancer.

Authors:  Don L Gibbons; Lauren A Byers; Jonathan M Kurie
Journal:  Mol Cancer Res       Date:  2014-01       Impact factor: 5.852

Review 2.  Transcriptional deregulation underlying the pathogenesis of small cell lung cancer.

Authors:  Dong-Wook Kim; Keun-Cheol Kim; Kee-Beom Kim; Colin T Dunn; Kwon-Sik Park
Journal:  Transl Lung Cancer Res       Date:  2018-02

Review 3.  Role of cell cycle regulators in lung carcinogenesis.

Authors:  Beatrice Eymin; Sylvie Gazzeri
Journal:  Cell Adh Migr       Date:  2010-01-16       Impact factor: 3.405

4.  Combined Neuroendocrine and Squamous Cell Carcinoma of the Sinonasal Tract: A Morphologic and Immunohistochemical Analysis and Review of Literature.

Authors:  Shweta Agarwal; Annemieke van Zante; Michaela L Granados
Journal:  Head Neck Pathol       Date:  2022-05-04

5.  A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype.

Authors:  Andrew J Syder; Sherif M Karam; Jason C Mills; Joseph E Ippolito; Habib R Ansari; Vidya Farook; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

6.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.

Authors:  Teresa Chiaverotti; Suzana S Couto; Annemarie Donjacour; Jian-Hua Mao; Hiroki Nagase; Robert D Cardiff; Gerald R Cunha; Allan Balmain
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

7.  Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer.

Authors:  Yian Wang; Weidong Wen; Yijun Yi; Zhongqiu Zhang; Ronald A Lubet; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2009-11-24

Review 8.  Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology.

Authors:  Hitoshi Kitamura; Takuya Yazawa; Hanako Sato; Koji Okudela; Hiroaki Shimoyamada
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

Authors:  Sadhna R Vora; Dejan Juric; Nayoon Kim; Mari Mino-Kenudson; Tiffany Huynh; Carlotta Costa; Elizabeth L Lockerman; Sarah F Pollack; Manway Liu; Xiaoyan Li; Joseph Lehar; Marion Wiesmann; Markus Wartmann; Yan Chen; Z Alexander Cao; Maria Pinzon-Ortiz; Sunkyu Kim; Robert Schlegel; Alan Huang; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-07-04       Impact factor: 31.743

10.  Pathogenesis of lung cancer signalling pathways: roadmap for therapies.

Authors:  E Brambilla; A Gazdar
Journal:  Eur Respir J       Date:  2009-06       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.